Previous 10 | Next 10 |
home / stock / mmirf / mmirf news
HALIFAX, NS / ACCESSWIRE / August 30, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) has completed, with its Transfer Agent, the process and has received confirmation by the TSX.v as follows: "Further to the resumption of trading of the shares of MedMira Inc., (the "Company"), the Exchange adv...
HALIFAX, NS / ACCESSWIRE / June 29, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2023. Corporate Update Summary During the third financial quarter of 2023, MedMira continued its focus on its regulatory and clinical trial wo...
HALIFAX, NS / ACCESSWIRE / April 3, 2023 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2023. Corporate Update Summary During the second financial quarter of 2023, MedMira continued its focus on its COVID-19 and Sexually Transmi...
HALIFAX, NS / ACCESSWIRE / February 20, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the singing of a multinational distribution agreement with Maternova, Inc. , Rhode Island, USA. Maternova is a US-based distribution company specialising in maternal and infant he...
HALIFAX, NS / ACCESSWIRE / January 11, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination antigen test available to detect SARS-CoV-2, Flu A and Flu B. The Company received...
HALIFAX, NS / ACCESSWIRE / January 3, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection - ( available: https://www.mdpi.com/2076-0817/12/1/77 ), in the ...
--News Direct-- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market. U.S. Regulatory Update on COVID-19 Produc...
Medmira (MMIRF): FQ3 net loss of C$0.34M.Revenue of C$0.06M (-33.3% Y/Y)Press Release For further details see: Medmira reports FQ3 results
Medmira (MMIRF): FQ2 net loss of C$0.41M.Revenue of C$0.34M (+277.8% Y/Y)Press Release For further details see: Medmira reports FQ2 results
New York, NY (1/13/2021) – As the most at-risk people begin to receive COVID-19 vaccinations, we are all looking forward to a post-pandemic world. As we transition back to something closer to normal life, however, the importance of rapid detection of any pathogen that could be hazard...
News, Short Squeeze, Breakout and More Instantly...
HALIFAX, NS / ACCESSWIRE / April 30, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) is pleased to announce the expansion of their commercialisation team by welcoming Ms. Rene Bell to the position of Vice President of Business Development. Ms. Bell brings over 20 years of Business Development a...
HALIFAX, NS / ACCESSWIRE / April 1, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended January 31, 2024. Corporate update During Q2 FY2024, MedMira received the US FDA 510(k) clearance for the HIV-2 claim on the Reveal ® G4 Rapid HIV...
HALIFAX, NS / ACCESSWIRE / March 13, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of a Canadian patent patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this...